Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement

Clinical Rheumatology

Volumn 31, Issue 9, 2012, Pages 1359-1364

  Azab, Noha A ^a   Rady, Hanaa M ^a   Marzouk, Samar A ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Pulmonary involvement; Systemic sclerosis; Tumor necrosis factor related apoptosis inducing ligand (TRAIL)

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; METHOTREXATE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASODILATOR AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG DISEASE; LUNG FUNCTION TEST; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCLERODERMA; SYSTEMIC SCLEROSIS;

ADULT; APOPTOSIS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG DISEASES; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84867849855     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2023-3     Document Type: Article

References (36)

1. White B (1996) Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 22:695-708 (Pubitemid 26396046)
2. Krammer PH (2000) CD95's deadly mission in the immune system. Nature 407:789-795
3. King C, Ilic A, Koelsch K, Sarvetnick N (2004) Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117:265-277 (Pubitemid 38496245)
4. Jelaska A, Korn JH (2000) Role of apoptosis and transforming growth factor beta 1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 43:2230
5. Wiley SR, Schooley K, Smolak PJ et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3(6):673-682 (Pubitemid 26091143)
6. Le Blanc HN, Ashkenazi A (2003) Apo 2L/TRAIL and its death decoy receptors. Cell Death Differ 10:66-75 (Pubitemid 36511833)
7. Jo M, Kim TH, Seol DWet al (2000) Apoptosis induced in normal human hepatocytes tumour necrosis factor-related apoptosisinducing ligand. Nat Med 6(5):564-567 (Pubitemid 30305907)
8. Nitsch R, Bechmann I, Deisz RA et al (2000) Human brain-cell death induced by tumour-necrosis factor-related apoptosisinducing ligand (TRAIL). Lancet 356:827-828
9. Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M (2005) Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 64:854-858 (Pubitemid 40733908)
10. Zai-Xing Y, Yan L, Hao W, Ye Z et al (2008) Preliminary clinical measurement of the expression of TNF-related apoptosis inducing ligand in patients with ankylosing spondylitis. J Clin Lab Anal 22 (2):138-145 (Pubitemid 351543946)
11. Huang WX, Huang P, Gomes A, Hillert J (2000) Apoptosis mediators FasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 55:928-934
12. Preliminary criteria for the classification of systemic sclerosis (scleroderma): Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and therapeutic Criteria Committee (1980) Arthritis Rheum 23:581-590
13. Le Roy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-205 (Pubitemid 18073738)
14. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324 (Pubitemid 18091653)
15. Clements PJ, Lachenbruch PA, Seibold JR et al (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20:1892-1896 (Pubitemid 24031593)
16. Warrick JH, Bhalla M, Schabel SI, Silver RM (1991) High resolution computed tomography in early scleroderma lung disease. J Rheumatol 18:1520-1528
17. Valat C, Diot E, Diot P (1998) Serum III procollagen is predictive of lung involvement in systemic sclerosis, but not serum I procollagen. Clin Exp Rheumatol 16:517-518 (Pubitemid 28370881)
18. Martin SJ, Grenn DR, Cotter TG (1994) Dicing with death: dissecting the components of the apoptosis machinery. Trends Biochem Sci 19:26-29
19. Kessel A, Rosner I, Rozenbaum M et al (2004) Increased CD8+ T cell apoptosis in scleroderma is associated with low levels of NFkappa B. J Clin Immunol 24:30-36 (Pubitemid 38375792)
20. Tsai HF, Lai JJ, Chou AH et al (2004) Induction of costimulation of human CD4 T cells by tumor necrosis factor-related apoptosisinducing ligand: possible role in T cell activation in systemic lupus erythematosus. Arthritis Rheum 50(2):629-639
21. Matsumura R, Umemiya K, Kagami M et al (2002) Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjogren's syndrome. Clin Exp Rheumatol 20:791-798 (Pubitemid 35446969)
22. Kaplan MJ, Lewis EE, Shelden EA et al (2002) The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 169:6020-6029 (Pubitemid 35291710)
23. Rus V, Atamas SP, Shustova Vet al (2002) Expression of cytokineand chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin Immunol 102:283-290 (Pubitemid 34259262)
24. Matsuyama W, Yamamoto M, Higashimoto I et al (2004) TNF related apoptosis inducing ligand is involved in neutropenia of systemic lupus erythematosus. Blood 104:184-191 (Pubitemid 38879856)
25. Yurovsky VV (2004) Cross-talk between TRAIL and TGF-β in regulation of collagen production in scleroderma lung disease. Arthritis Res Ther 6(Suppl 1):26
26. Diot E, Boissinot E, Asquier E et al (1998) Relationship between abnormalities on high resolution computed tomography and pulmonary function in systemic sclerosis. Chest 114:1623-1629 (Pubitemid 128487485)
27. Bouros D, Wells AU, Nicholson AG et al (2002) Histopathologic subset of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165:1581-1586 (Pubitemid 34693935)
28. Tomasek JJ, Gabbiani G, Hinz B et al (2002) Myofibroblasts and mechano-regulation of connective tissue remodeling. Nat Rev Mol Cell Biol 3:349-363 (Pubitemid 34619269)
29. Harrison NK, Myers AR, Corrin B et al (1991) Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 144(3 Pt 1):706-713
30. Yurovsky VV (2003) Tumor necrosis factor-related apoptosisinducing ligand enhances collagen production by human lung fibroblasts. Am J Respir Cell Mol Biol 28:225-231 (Pubitemid 36169652)
31. Atamas SP, Yurovsky VV, Wise R, Wigley FM, Goter Robinson CJ, Henry P, Alms WJ, White B (1999) Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 42:1168-1178 (Pubitemid 29268953)
32. Freiberg RA, Spencer DM, Choate KA, Duh HJ, Schreiber SL, Crabtree GR, Khavari PA (1997) Fas signal transduction triggers either proliferation or apoptosis in human fibroblasts. J Invest Dermatol 108:215-219 (Pubitemid 27061035)
33. Chou AH, Tsai HF, Lin LL et al (2001) Enhanced proliferation and increased IFN-production in T cells by signal transduced through TNF-related apoptosis-inducing ligand. J Immunol 167:1347-1352
34. Halaas O, Vik R, Ashkenazi A, Espevik T (2000) Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand J Immunol 51:244-250 (Pubitemid 30151507)
35. Luzina I, Atamas S, Lockatell L, Rus V (2011) CCL18-mediated pulmonary infiltration of T lymphocytes is independent of TRAIL but requires DR5. J Immunol 186:102.20
36. Fries KM, Blieden T, Looney RJ et al (1994) Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. Clin Immunol Immunopathol 72:283-292 (Pubitemid 24275206)